Nexien BioPharma, Inc.
NXEN
$0.0095
$0.000.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 79.10% | -74.68% | -2.43% | -77.09% | -81.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 79.10% | -74.68% | -2.43% | -77.09% | -81.64% |
| Operating Income | -79.10% | 74.68% | 2.43% | 77.09% | 81.64% |
| Income Before Tax | -61.22% | 57.28% | 7.59% | 33.42% | 73.82% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -61.22% | 57.28% | 7.59% | 33.42% | 73.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -61.22% | 57.28% | 7.59% | 33.42% | 73.82% |
| EBIT | -79.10% | 74.68% | 2.43% | 77.09% | 81.64% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -50.00% | 58.33% | 13.33% | 38.46% | 73.33% |
| Normalized Basic EPS | -50.00% | 57.14% | 11.11% | 37.50% | 77.78% |
| EPS Diluted | -50.00% | 58.33% | 13.33% | 38.46% | 73.33% |
| Normalized Diluted EPS | -50.00% | 57.14% | 11.11% | 37.50% | 77.78% |
| Average Basic Shares Outstanding | 8.69% | 9.13% | 7.83% | 5.98% | 5.16% |
| Average Diluted Shares Outstanding | 8.69% | 9.13% | 7.83% | 5.98% | 5.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |